These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 2624598

  • 21. Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism.
    Vezza R, Spina D, Tallarida RJ, Nathan M, Page CP, Gresele P.
    Thromb Haemost; 1997 Nov; 78(5):1385-91. PubMed ID: 9408024
    [Abstract] [Full Text] [Related]

  • 22. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
    Fiedler VB, Perzborn E, Seuter F, Rosentreter U, Böshagen H.
    Arzneimittelforschung; 1989 Dec; 39(12):1527-30. PubMed ID: 2624600
    [Abstract] [Full Text] [Related]

  • 23. Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: involvement of endothelium generated thromboxane.
    Fabi F, Argiolas L, Ruvolo G, del Basso P.
    Br J Pharmacol; 1998 May; 124(1):101-10. PubMed ID: 9630349
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Inhibition of smooth muscle cell calcium mobilization and aortic ring contraction by lactone vastatins.
    Escobales N, Crespo MJ, Altieri PI, Furilla RA.
    J Hypertens; 1996 Jan; 14(1):115-21. PubMed ID: 12013483
    [Abstract] [Full Text] [Related]

  • 27. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
    Fitzgerald DJ, Doran J, Jackson E, FitzGerald GA.
    J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161
    [Abstract] [Full Text] [Related]

  • 28. Biosynthesis and biological properties of prostaglandin endoperoxides and thromboxane A2.
    Svensson J.
    Acta Biol Med Ger; 1978 Feb; 37(5-6):731-40. PubMed ID: 742285
    [Abstract] [Full Text] [Related]

  • 29. Mechanism of antagonism of thromboxane receptors in vascular smooth muscle.
    Yanagisawa A, Smith JA, Brezinski ME, Lefer AM.
    Eur J Pharmacol; 1987 Jan 06; 133(1):89-96. PubMed ID: 3030773
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist.
    Hall RA, Gillard J, Guindon Y, Letts G, Champion E, Ethier D, Evans J, Ford-Hutchinson AW, Fortin R, Jones TR.
    Eur J Pharmacol; 1987 Mar 17; 135(2):193-201. PubMed ID: 3582493
    [Abstract] [Full Text] [Related]

  • 32. Non-specific antagonism against thromboxane A2 of 7-ethoxycarbonyl-6,8-dimethyl-4-hydroxymethyl-1(2H)-phthalazinone (EG-626) in contraction of isolated smooth muscles.
    Harada Y, Tanaka K, Katori M.
    Prostaglandins; 1979 Jun 17; 17(6):957-66. PubMed ID: 504697
    [Abstract] [Full Text] [Related]

  • 33. Characterization of Bay U 3405, a novel thromboxane A2/endoperoxide receptor antagonist.
    Perzborn E, Fiedler VB, Seuter F, Stasch JP, Weber H, Sander E, Böshagen H, Rosentreter U.
    Stroke; 1990 Dec 17; 21(12 Suppl):IV143-5. PubMed ID: 2148034
    [Abstract] [Full Text] [Related]

  • 34. Increased thromboxane production after whole body irradiation.
    Sochanowicz B, Przygoda E, Dancewicz AM.
    Acta Biochim Pol; 1990 Dec 17; 37(1):103-8. PubMed ID: 2087899
    [Abstract] [Full Text] [Related]

  • 35. Effects of the thromboxane-receptor antagonist L-636,499 on feline cerebral arteries.
    Uski TK, Andersson KE.
    Acta Physiol Scand; 1986 Dec 17; 128(4):605-11. PubMed ID: 2949488
    [Abstract] [Full Text] [Related]

  • 36. L-641,953 (R-8-fluoro-dibenzo[b, f]thiepin-3-carboxylic acid-5-oxide): a novel thromboxane-prostaglandin endoperoxide antagonist.
    Hall RA, Rokach JR, Bélanger P, Bianchi L, Ethier D, Ford-Hutchinson AW, Girard Y, Hamel P, Hamel R, Lord A.
    Can J Physiol Pharmacol; 1987 Apr 17; 65(4):509-14. PubMed ID: 3607600
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Dominant contribution of 5-hydroxytryptamine over thromboxane A2 in contractile response of rabbit isolated aortic preparation to thrombin activated platelets.
    Nakanishi H, Matsuoka I, Ono T, Nakahata N.
    Res Commun Mol Pathol Pharmacol; 1995 Nov 17; 90(2):255-67. PubMed ID: 8747793
    [Abstract] [Full Text] [Related]

  • 40. Relaxation of carbocyclic thromboxane A2-induced contractions of isolated coronary arteries by nifedipine.
    Towart R, Perzborn E.
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Feb 17; 318(3):249-51. PubMed ID: 7063050
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.